Tandem Diabetes Care (NASDAQ:TNDM) traded higher on Tuesday after Citi upgraded the insulin pump maker to Neutral from Sell, citing a shift in its risk-reward setup following the company’s ...

What Happened? A number of stocks fell in the afternoon session after the major indices continued to pull back, with ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) has been given an average rating of “Moderate Buy” by the seventeen analysts that are presently covering the firm, MarketBeat.com ...

Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $11 from $10.35 and keeps a Neutral rating on the shares. The firm adjusted ...

In the last three months, 4 analysts have published ratings on Tandem Diabetes Care TNDM, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...

Tandem Diabetes Care (NASDAQ:TNDM – Free Report) had its price target hoisted by Canaccord Genuity Group from $58.00 to $59.00 in a report published on Thursday morning,Benzinga reports. They ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on ...

Tandem Diabetes Care, Inc. TNDM is likely to grow in the coming quarters due to its impressive streak of new product offerings. The company is actively pursuing growth through strategic ...

Tandem Diabetes Care Inc, a leading provider in the realm of insulin delivery and diabetes technology, is revolutionizing diabetes management with its cutting-edge solutions.